Global Mpox Outbreaks Highlight Need for Diversified Vaccine Supply, GeoVax Labs at Forefront

The global health community faces a pressing challenge as Mpox outbreaks continue to expand across continents, necessitating a diversified and scalable vaccine supply. GeoVax Labs, Inc. has positioned its GEO-MVA vaccine candidate as a pivotal solution, especially after the European Medicines Agency (EMA) endorsed a streamlined development pathway. This regulatory advancement allows for a single Phase 3 immuno-bridging trial to support a Marketing Authorisation Application (MAA), significantly cutting down development time without compromising safety or efficacy standards.

Recent findings from the Airfinity July 2025 Mpox Report paint a concerning picture of the Mpox landscape, with Clade I cases now reported worldwide, including in China, the United Kingdom, Italy, and the U.S. The report also sheds light on the risk of vertical transmission from mother to child during pregnancy, highlighting the imperative for vaccines that are not only effective but also come with comprehensive safety data and are accessible globally. GeoVax's GEO-MVA vaccine, with its plans for modernized manufacturing processes, stands out as a scalable and cost-effective alternative to existing MVA-based vaccines.

David Dodd, GeoVax's Chairman and CEO, emphasized the critical need for a diversified Mpox vaccine supply to combat the silent spread of Clade I and the rise in breakthrough infections. The company is in active discussions with global health organizations and governments to expedite the deployment of GEO-MVA in regions grappling with outbreaks. This initiative aims to bolster the global Mpox vaccine infrastructure, ensuring it is robust enough to handle current and future challenges. For more information on the GEO-MVA vaccine candidate, visit https://www.geovax.com.